by myNEO Tx Admin | Jan 22, 2025 | News
We are thrilled to announce that myNEO Therapeutics has partnered with the University of Liverpool to launch a groundbreaking Phase 1 clinical trial focused on developing a personalised therapeutic cancer vaccine for patients with Non-Small Cell Lung Cancer (NSCLC)....by myNEO Tx Admin | Dec 4, 2024 | Team events
At myNEO Therapeutics, we recently hosted a DIY Waffle Day where teams got together to make and decorate waffles. It was a fun way to connect and enjoy some tasty treats. 🧇by myNEO Tx Admin | Dec 4, 2024 | News
Our CEO, Cedric Bogaert, shares exciting news: “I’m glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vaccine) with LinkedIn as well. We’ve presented these results in the past month on several scientific conferences,...by myNEO Tx Admin | Dec 4, 2024 | News
🚀 Advancing Immunotherapy through Antigen Target ScreeningWe’re excited to announce the creation of an innovative antigen target library, built from extensive screenings across 1,000+ patients with diverse cancer indications. This well-validated library is one of the...by myNEO Tx Admin | Oct 2, 2024 | Team events
At myNEO Therapeutics we always celebrate the birthdays of every colleague with delicious cakes, smiles, and birthday cheer! Here’s to more fun and teamwork in the year ahead!ÂThe process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).